Pharmacological Evaluation Of Saroglitazar And Gemfibrozil Combination Therapy In The Treatment Of Diabetic Dyslipidemia

Abstract

Introduction

Diabetics have an increased cardiovascular risk. This risk gets exaggerated by lipid abnormalities additionally. Diabetics have an increased propensity to develop dyslipidemia. Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increased triglyceride & low-density lipoprotein (LDL) levels, decreased high-density lipoprotein levels.

Methodology

From the pilot study potent dose of Saroglitazar and Gemfibrozil were selected for this study. In this study, the experimental rats were divided into five groups of six animals in each group.

Results

Combination therapy shows decrease in lipid profile, atherogenic index, histopathological studies of different organs and Insulin levels compared to individual drugs and shows better therapeutic efficacy.

Conclusion

Hence the combination of Saroglitazar and Gemfibrozil has shown good safety profile and may represent a novel therapeutic agent that will fulfill the unmet needs in T2DM and diabetic dyslipidemia.